South Korea to Allow Prescription of Mifepristone for Early Abortions

The South Korean government plans to officially allow the prescription and dispensing of mifepristone, a medication for medical abortions, for women within nine weeks of pregnancy starting as early as the first quarter of next year. For the first two years, prescriptions will be limited to direct orders from physicians and in-hospital dispensing to ensure patient safety. This decision comes seven years after the Constitutional Court ruled that the abortion law was unconstitutional.

Mifepristone is a combination therapy that blocks progesterone and induces uterine contractions with misoprostol. The World Health Organization designated it as an essential medicine in 2005. Since France first approved it in 1988, over 90 countries have legalized its use. Japan also formally approved the use of oral medications for women within nine weeks of pregnancy in 2023.

Since the Constitutional Court's decision, legislative efforts have stalled, leaving a gap in the law. Although the penal provisions have lost their effect, the absence of approved medications has forced women to rely on unregulated online markets or overseas purchases, risking their health and lives. The expedited review and approval of this medication marks a turning point by curbing dangerous underground distribution and bringing women's health rights under public health protections.

However, social tensions remain high. Women's groups welcome the decision but argue that the nine-week limit and in-hospital dispensing significantly restrict access, calling for health insurance coverage and the right to self-administer the medication. The medical community emphasizes the need for ultrasound diagnostics and direct physician oversight to address complications like incomplete abortions or excessive bleeding, urging for legal liability relief and safety guidelines. Religious groups express concerns about potential drug misuse and violations of fetal rights.

Before the medication is available on the market, institutional improvements are necessary. Most importantly, addressing 'economic barriers' is crucial. If the medication is introduced as a non-reimbursable item, vulnerable women may again turn to underground transactions due to high costs. Efforts to include it in health insurance coverage and transparent pricing must be prioritized. The requirements for parental consent when prescribing to minors should also be carefully considered. A counseling system that provides medical and emotional support must be established to avoid leaving vulnerable youth in a support gap.

Abortion is not merely a matter of debate or a political tool. It falls within the realm of a national health and welfare system that guarantees women's bodily autonomy, reproductive health, and quality of life. Hospital dispensing within nine weeks is a practical compromise to fill the seven-year gap and represents a first step forward. The government and the National Assembly must listen to the rational voices of the medical and women's communities to establish standard clinical guidelines and complete subsequent legislation. Beyond the decision to 'legalize,' it is the state's responsibility to create a universal healthcare infrastructure that allows all women to receive safe treatment without exclusion or risk.